SG11201811178UA - Adenoviral vector - Google Patents
Adenoviral vectorInfo
- Publication number
- SG11201811178UA SG11201811178UA SG11201811178UA SG11201811178UA SG11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA SG 11201811178U A SG11201811178U A SG 11201811178UA
- Authority
- SG
- Singapore
- Prior art keywords
- oxford
- orcrb
- international
- oxfordshire
- roosevelt
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 241000701161 unidentified adenovirus Species 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 244000028344 Primula vulgaris Species 0.000 abstract 1
- 235000016311 Primula vulgaris Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1610967.0A GB2549809C (en) | 2016-06-23 | 2016-06-23 | Vector |
PCT/GB2017/051851 WO2017221031A1 (en) | 2016-06-23 | 2017-06-23 | Adenoviral vector |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811178UA true SG11201811178UA (en) | 2019-01-30 |
Family
ID=56891578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811178UA SG11201811178UA (en) | 2016-06-23 | 2017-06-23 | Adenoviral vector |
Country Status (13)
Country | Link |
---|---|
US (2) | US11306325B2 (ko) |
EP (2) | EP3943604A1 (ko) |
JP (2) | JP7187451B2 (ko) |
KR (1) | KR102205908B1 (ko) |
CN (1) | CN109790548B (ko) |
AU (1) | AU2017282102B2 (ko) |
CA (1) | CA3027686A1 (ko) |
DK (1) | DK3475433T3 (ko) |
ES (1) | ES2883354T3 (ko) |
GB (1) | GB2549809C (ko) |
MX (1) | MX2018016074A (ko) |
SG (1) | SG11201811178UA (ko) |
WO (1) | WO2017221031A1 (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
BR112020019942A2 (pt) * | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
GB201818084D0 (en) | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
CA3140019A1 (en) * | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
CN113088538A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法 |
CN113088530A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法 |
WO2021158815A1 (en) * | 2020-02-05 | 2021-08-12 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
US12023376B1 (en) | 2020-04-17 | 2024-07-02 | Triad National Security, Llc | Conserved region T cell vaccines for coronavirus and methods of use |
RU2720614C9 (ru) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
CN114845733A (zh) * | 2020-08-22 | 2022-08-02 | 俄罗斯联邦卫生部的联邦国家预算机构“以名誉院士N.F.加马列亚命名的国家流行病学和微生物学研究中心” | 抗严重急性呼吸综合征病毒SARS-CoV-2的表达载体 |
WO2022122036A1 (zh) * | 2020-12-10 | 2022-06-16 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原、药物组合物及其应用 |
CN112552380B (zh) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
CN112831524B (zh) * | 2021-02-20 | 2023-06-13 | 苏州相奕生物技术有限公司 | 人工改造的重组腺病毒载体、由其包装的病毒及其应用 |
CN116103242A (zh) * | 2023-01-10 | 2023-05-12 | 潍坊医学院 | 一种靶向治疗结核病的esat6-car-t及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE449105T1 (de) * | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
AU2010209938A1 (en) * | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
CA2851251C (en) * | 2011-10-05 | 2023-09-12 | Genvec, Inc. | Simian (gorilla) adenovirus or adenoviral vectors and methods of use |
GB201318084D0 (en) * | 2013-10-11 | 2013-11-27 | Isis Innovation | Malaria vaccination |
BR112016008806A2 (pt) | 2013-11-01 | 2017-10-03 | Pfizer | Vetores para expressão de antígenos associados à próstata |
GB201413530D0 (en) * | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
-
2016
- 2016-06-23 GB GB1610967.0A patent/GB2549809C/en active Active
-
2017
- 2017-06-23 CA CA3027686A patent/CA3027686A1/en active Pending
- 2017-06-23 JP JP2019520507A patent/JP7187451B2/ja active Active
- 2017-06-23 KR KR1020197002318A patent/KR102205908B1/ko active IP Right Grant
- 2017-06-23 AU AU2017282102A patent/AU2017282102B2/en active Active
- 2017-06-23 SG SG11201811178UA patent/SG11201811178UA/en unknown
- 2017-06-23 CN CN201780039028.8A patent/CN109790548B/zh active Active
- 2017-06-23 EP EP21182840.5A patent/EP3943604A1/en active Pending
- 2017-06-23 DK DK17734440.5T patent/DK3475433T3/da active
- 2017-06-23 US US16/310,281 patent/US11306325B2/en active Active
- 2017-06-23 ES ES17734440T patent/ES2883354T3/es active Active
- 2017-06-23 EP EP17734440.5A patent/EP3475433B9/en active Active
- 2017-06-23 WO PCT/GB2017/051851 patent/WO2017221031A1/en unknown
- 2017-06-23 MX MX2018016074A patent/MX2018016074A/es unknown
-
2022
- 2022-01-28 US US17/587,376 patent/US11970709B2/en active Active
- 2022-08-15 JP JP2022129264A patent/JP7333857B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US11306325B2 (en) | 2022-04-19 |
ES2883354T3 (es) | 2021-12-07 |
CA3027686A1 (en) | 2017-12-28 |
CN109790548A (zh) | 2019-05-21 |
EP3475433B1 (en) | 2021-07-21 |
KR20190020131A (ko) | 2019-02-27 |
WO2017221031A1 (en) | 2017-12-28 |
US20220220507A1 (en) | 2022-07-14 |
EP3475433B9 (en) | 2022-08-24 |
JP2019519252A (ja) | 2019-07-11 |
EP3943604A1 (en) | 2022-01-26 |
AU2017282102A1 (en) | 2019-01-03 |
JP7333857B2 (ja) | 2023-08-25 |
US20190175716A1 (en) | 2019-06-13 |
GB2549809C (en) | 2022-11-30 |
GB2549809B (en) | 2019-04-03 |
AU2017282102B2 (en) | 2023-03-23 |
JP7187451B2 (ja) | 2022-12-12 |
GB201610967D0 (en) | 2016-08-10 |
DK3475433T3 (da) | 2021-08-16 |
MX2018016074A (es) | 2019-09-09 |
EP3475433A1 (en) | 2019-05-01 |
US11970709B2 (en) | 2024-04-30 |
JP2022159418A (ja) | 2022-10-17 |
KR102205908B1 (ko) | 2021-01-22 |
CN109790548B (zh) | 2024-03-22 |
GB2549809A (en) | 2017-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811178UA (en) | Adenoviral vector | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201808709VA (en) | T cell receptors | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201808750PA (en) | T cell receptors | |
SG11201407923TA (en) | Liquid optical adhesive compositions | |
SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201408054RA (en) | Pegylated oxm variants | |
SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
SG11201408746XA (en) | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201911572YA (en) | Adenoviral vectors | |
SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
SG11201806538WA (en) | Engineered antigen presenting cells and uses thereof |